Amplification of the ERBB2 gene (encoding for HER2 protein) is detected by fluorescent in
situ hybridization (FISH) in human breast and esophagogastric cancer tissue specimens.

PD-L1 IHC 22C3 is a qualitative immunohistochemical assay using Monoclonal Mouse Anti-PD-L1, Clone 22C3 intended for use in the detection of PD-L1 protein. PD-L1 IHC 22C3 is indicated as an aid in identifying NSCLC patients for treatment with KEYTRUDA® (pembrolizumab).

Ki67 is a nuclear protein expressed in proliferating cells, which is detected by a primary monoclonal rabbit anti-human Ki67 antibody (clone 30-9). Ki67 expression level is determined by the percentage of appropriately stained tumor cells.

Consultation by a Genoptix Hematopathologist on previously diagnosed cases. We require appropriate clinical data and slides, as well as the most recent morphology report and laboratory test results.

When serial or subsequent COMPASS® evaluations are requested on the same patient and deemed clinically appropriate by a Genoptix Hematopathologist, Genoptix will automatically provide a CHART® report, unless otherwise indicated by the ordering physician. CHART® includes all medically necessary technologies, and a consultative review and correlation with relevant prior findings and intervening treatment by a Genoptix Hematopathologist.

The client’s pathologist must provide the cytogenetics report to Genoptix. COMPASS® Select includes the COMPASS® consultation report, clinical pathology evaluation, blood or bone marrow morphology (up to 20 stains and/or IHC antibodies), flow cytometry (up to 40 antibodies), and molecular tests as medically necessary.

The client’s pathologist must provide the flow cytometry report to Genoptix. COMPASS® Select includes the COMPASS® consultation report, clinical pathology evaluation, bone marrow morphology (up to 20 stains and/or IHC antibodies), cytogenetics and/or fluorescent in situ hybridization (FISH) (up to 14 probes), and molecular tests as medically necessary.

The client’s pathologist must provide the morphology report to Genoptix. COMPASS® Select includes the COMPASS® consultation report, clinical pathology evaluation, flow cytometry (up to 40 antibodies), cytogenetics and/or fluorescent in situ hybridization (FISH) (up to 14 probes), and molecular tests as medically necessary.

Includes COMPASS® consultation report, clinical pathology evaluation, bone marrow morphology (up to 20 stains and/or IHC antibodies), flow cytometry (up to 40 antibodies), cytogenetics and/or fluorescent in situ hybridization (FISH) (up to 14 probes), and molecular tests as medically necessary.

Includes COMPASS® consultation report, clinical pathology evaluation, blood morphology (up to 10 cytochemical stains), flow cytometry (up to 40 antibodies), cytogenetics and/or fluorescent in situ hybridization (FISH) (up to 14 probes), and molecular tests as medically necessary.